Mestag Therapeutics was founded in 2020 by leading scientists, drug developers and investors to pioneer new medicines for people affected by inflammatory disease and cancer.
Our approach builds on recent data which points to resident cells called fibroblasts as playing a key role in driving disease. Mestag’s mission is to lead this emerging field in developing impactful precision medicines for patients through our understanding of activated fibroblast populations and their influence on immune effector cells.
Our company was created by global thought-leaders in fibroblast biology, is supported by experienced international investors and is powered by our team of scientists based in Cambridge, UK.
FIBROBLASTS. REIMAGINED.
About Us
We aim to lead the field in discovering, developing and delivering impactful precision medicines through unparalleled insight into disease-driving fibroblast subpopulations.
Our Science
We are developing a portfolio of first-in-class therapeutics targeting novel fibroblast-associated biology across the inflammatory disease and
tumour micro-environments.
Work With Us
We are excited to hear from smart, passionate people who are driven to improve the lives of patients with inflammatory disease and cancer.
